Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.005
Zhihui He, Jiangzheng Zeng, F. Huang, Junhua Lei
Objective To investigate the effect and safety of apatinib in the treatment of advanced gastric cancer. Methods A total of 60 patients with advanced gastric cancer at the first Affiliated Hospital of Hainan Medical College from April 2015 to October 2018 were retrospectively analyzed, and all patients were divided into two groups according to the treatment method, each group of 30 cases. The control group was treated with conventional treatment, and the observation group was given the treatment of apatinib on the basis of the control group, and then the clinical curative effect and adverse reactions were compared between the two groups. Results There were 2 cases (6.67%) of complete remission in the observation group, 14 cases (46.67%) of partial remission, 10 cases (33.33%) of stability and 4 cases (13.33%) of disease progression, and the total effective rate was 53.33% (16/30). The control group had no complete remission, 8 cases (26.67%) of partial remission, 11 cases (36.67%) of stability and 11 cases (36.67%) of disease progression, and the total effective rate was 26.67% (8/30). The difference of total effective rate between the two groups was statistically significant (χ 2 = 4.444, P = 0.035). There was no significant difference in the level of tumor marker carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA125, cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) between the two groups before and after treatment (all P > 0.05). The incidence of hand-foot syndrome and hypertension in the observation group was higher than that in the control group [73.33% (22/30) vs. 43.33% (13/30), H = 5.554, P = 0.018; 76.67% (23/30) vs. 46.67% (14/30), H = 5.711, P = 0.017]. The incidence of proteinuria, bone marrow suppression and the cardiac adverse reactions in the observation group was higher than that in the control group [63.33% (19/30) vs. 33.33% (10/30), H = 3.300, P = 0.069; 60.00%(18/30) vs. 36.67% (11/30), H = 5.455, P = 0.071; 53.33% (16/30) vs. 30.00% (9/30), H = 3.360, P = 0.067]. Conclusion Apatinib is effective in the treatment of advanced gastric cancer, but the occurrence of hand-foot syndrome and hypertension should be paid close attention during the treatment. Key words: Stomach neoplasms; Tumor markers, biological; Molecular targeted therapy; Apatinib; Comparative effectiveness research; Adverse effects
{"title":"Efficacy and safety observation of apatinib in treatment of advanced gastric cancer","authors":"Zhihui He, Jiangzheng Zeng, F. Huang, Junhua Lei","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.005","url":null,"abstract":"Objective \u0000To investigate the effect and safety of apatinib in the treatment of advanced gastric cancer. \u0000 \u0000 \u0000Methods \u0000A total of 60 patients with advanced gastric cancer at the first Affiliated Hospital of Hainan Medical College from April 2015 to October 2018 were retrospectively analyzed, and all patients were divided into two groups according to the treatment method, each group of 30 cases. The control group was treated with conventional treatment, and the observation group was given the treatment of apatinib on the basis of the control group, and then the clinical curative effect and adverse reactions were compared between the two groups. \u0000 \u0000 \u0000Results \u0000There were 2 cases (6.67%) of complete remission in the observation group, 14 cases (46.67%) of partial remission, 10 cases (33.33%) of stability and 4 cases (13.33%) of disease progression, and the total effective rate was 53.33% (16/30). The control group had no complete remission, 8 cases (26.67%) of partial remission, 11 cases (36.67%) of stability and 11 cases (36.67%) of disease progression, and the total effective rate was 26.67% (8/30). The difference of total effective rate between the two groups was statistically significant (χ 2 = 4.444, P = 0.035). There was no significant difference in the level of tumor marker carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA125, cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) between the two groups before and after treatment (all P > 0.05). The incidence of hand-foot syndrome and hypertension in the observation group was higher than that in the control group [73.33% (22/30) vs. 43.33% (13/30), H = 5.554, P = 0.018; 76.67% (23/30) vs. 46.67% (14/30), H = 5.711, P = 0.017]. The incidence of proteinuria, bone marrow suppression and the cardiac adverse reactions in the observation group was higher than that in the control group [63.33% (19/30) vs. 33.33% (10/30), H = 3.300, P = 0.069; 60.00%(18/30) vs. 36.67% (11/30), H = 5.455, P = 0.071; 53.33% (16/30) vs. 30.00% (9/30), H = 3.360, P = 0.067]. \u0000 \u0000 \u0000Conclusion \u0000Apatinib is effective in the treatment of advanced gastric cancer, but the occurrence of hand-foot syndrome and hypertension should be paid close attention during the treatment. \u0000 \u0000 \u0000Key words: \u0000Stomach neoplasms; Tumor markers, biological; Molecular targeted therapy; Apatinib; Comparative effectiveness research; Adverse effects","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42463367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.017
Chen Wang
Long non-coding RNA (lncRNA) is a kind of regulatory RNA molecules with a length of more than 200nt, which can be involved in epigenetic modification of cells and gene expression by altering the chromatin status. HOTAIR is a kind of lncRNA, and some researches have found that HOTAIR may involved in the occurrence and development of leukemia, and it is obviously related to the diagnosis, treatment and prognosis of leukemia. This review summarizes the discovery, function, detection methods of HOTAIR and the latest research progress in leukemia, to provide new ideas for the diagnosis, individualized treatment and prognosis of leukemia. Key words: Leukemia; Long non-coding RNA; Diagnosis; HOTAIR; Prognosis
{"title":"Progress of long non-coding RNA HOTAIR in leukemia","authors":"Chen Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.017","url":null,"abstract":"Long non-coding RNA (lncRNA) is a kind of regulatory RNA molecules with a length of more than 200nt, which can be involved in epigenetic modification of cells and gene expression by altering the chromatin status. HOTAIR is a kind of lncRNA, and some researches have found that HOTAIR may involved in the occurrence and development of leukemia, and it is obviously related to the diagnosis, treatment and prognosis of leukemia. This review summarizes the discovery, function, detection methods of HOTAIR and the latest research progress in leukemia, to provide new ideas for the diagnosis, individualized treatment and prognosis of leukemia. \u0000 \u0000 \u0000Key words: \u0000Leukemia; Long non-coding RNA; Diagnosis; HOTAIR; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44736314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.002
Xia Liu, Zhengjie Han, Tingting Liu, Jieh-Yuan Liu
Objective To investigate the effect of cinobufacin combined with As2O3 on the angiogenesis of subcutaneous transplantation tumor in colorectal carcinoma BALB/C nude mice. Methods The colorectal carcinoma transplantation tumor model of BALB/C nude mice was established and divided into 4 groups, 5 mice in each group. The growth state of nude mice was observed by injecting the corresponding reagents into the tumor in As2O3 group, cinobufacin group, cinobufacin combined As2O3 group and the blank control group (replaced by phosphate buffer), respectively. The nude mice were killed two weeks later, and the tumor tissues, liver and kidney tissues and orbital vein blood were taken. The tumor volume inhibition rate and mass inhibition rate of nude mice were calculated. The histomorphology of tumor, liver and kidney and blood routine were detected. The expressions of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), fibroblast growth factor-basic (b-FGF) and CD105 in transplanted tumor tissues were detected by using immunohistochemistry method, and the microvascular density (MVD) of transplanted tumor in nude mice was evaluated. Western blot method was used to detect the protein expression levels of VEGF, EGFR and b-FGF. Results After 2 weeks of administration, the tumor volume and tumor mass in As2O3 group, cinobufacin group and cinobufacin combined As2O3 group were lower than those in the blank control group. The volume inhibition rate was 16%, 17%, 72%, and the mass inhibition rate was 31%, 33%, 78%, respectively, and the difference was statistically significant (all P 0.05), and cinobufacin combined As2O3 group had the most obvious therapeutic effects (all P 0.05), and cinobufacin combined As2O3 group had the most significant decrease in the marker changes, and there was a significant difference compared with the other groups (all P 0.05). Conclusions Cinobufacin and As2O3 show synergistic effects in the tumor angiogenesis and inhibition of transplantation tumor growth of colorectal cancer BALB/C nude mice. Moreover, cinobufacin and As2O3 have no obvious toxicity to the hepatic, kidney and hematopoietic tissues. Key words: Colonic neoplasms; Cinobufacin; Arsenites; Nude mice; Angiogenesis
{"title":"Effect of cinobufacin combined with As2O3 on the angiogenesis of subcutaneous colorectal carcinoma transplantation tumor in BALB/C nude mice","authors":"Xia Liu, Zhengjie Han, Tingting Liu, Jieh-Yuan Liu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.002","url":null,"abstract":"Objective \u0000To investigate the effect of cinobufacin combined with As2O3 on the angiogenesis of subcutaneous transplantation tumor in colorectal carcinoma BALB/C nude mice. \u0000 \u0000 \u0000Methods \u0000The colorectal carcinoma transplantation tumor model of BALB/C nude mice was established and divided into 4 groups, 5 mice in each group. The growth state of nude mice was observed by injecting the corresponding reagents into the tumor in As2O3 group, cinobufacin group, cinobufacin combined As2O3 group and the blank control group (replaced by phosphate buffer), respectively. The nude mice were killed two weeks later, and the tumor tissues, liver and kidney tissues and orbital vein blood were taken. The tumor volume inhibition rate and mass inhibition rate of nude mice were calculated. The histomorphology of tumor, liver and kidney and blood routine were detected. The expressions of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), fibroblast growth factor-basic (b-FGF) and CD105 in transplanted tumor tissues were detected by using immunohistochemistry method, and the microvascular density (MVD) of transplanted tumor in nude mice was evaluated. Western blot method was used to detect the protein expression levels of VEGF, EGFR and b-FGF. \u0000 \u0000 \u0000Results \u0000After 2 weeks of administration, the tumor volume and tumor mass in As2O3 group, cinobufacin group and cinobufacin combined As2O3 group were lower than those in the blank control group. The volume inhibition rate was 16%, 17%, 72%, and the mass inhibition rate was 31%, 33%, 78%, respectively, and the difference was statistically significant (all P 0.05), and cinobufacin combined As2O3 group had the most obvious therapeutic effects (all P 0.05), and cinobufacin combined As2O3 group had the most significant decrease in the marker changes, and there was a significant difference compared with the other groups (all P 0.05). \u0000 \u0000 \u0000Conclusions \u0000Cinobufacin and As2O3 show synergistic effects in the tumor angiogenesis and inhibition of transplantation tumor growth of colorectal cancer BALB/C nude mice. Moreover, cinobufacin and As2O3 have no obvious toxicity to the hepatic, kidney and hematopoietic tissues. \u0000 \u0000 \u0000Key words: \u0000Colonic neoplasms; Cinobufacin; Arsenites; Nude mice; Angiogenesis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44465136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.009
B. Nie, Xin Huang, Lin Sun, Xiaolong Liu, L. Kong, Zi-fen Gao
Objective To analyze the clinicopathological features of the posttransplant lymphoproliferative disorders (PTLD) and to improve the diagnostic levels. Methods The clinical data of 11 patients diagnosed with PTLD between January 2008 and January 2018 from Henan Provincial People's Hospital, Peking University Science Center and the Affiliated Third Hospital of Peking University were collected. The clinicopathological features and the potential prognostic predictors were retrospectively analyzed by using immunohistochemical staining, EB virus in situ hybridization, fluorescence in situ hybridization and gene sequencing. Results There were 9 males and 2 females in 11 PTLD patients, and the median age of the total patients was 18 years old (3-34 years old). The median time of 9 cases who underwent hematopoietic stem cell transplantation developing PTLD was 4 months (2-24 months) after the transplantation. The other 2 cases undergoing solid organ transplantation (SOT) occurred PTLD after 6 months and 13 months, respectively. The lymph node was the most common site to be involved (9 cases), 1 case occurred in liver and 1 case occurred in nasopharynx site. Among 11 patients, 3 cases were classified as polymorphic PTLD (P-PTLD) and the other 8 cases were monomorphic PTLD (M-PTLD). EB virus of all cases was positive, and 8 cases of M-PTLD were classified as diffuse large B-cell lymphoma (DLBCL). Fluorescence in situ hybridization was used to detect bcl-2, myc, IGH and A20 gene, and only one case had the gene break of IGH, while other cases didn't find any other abnormalities. Ig gene clone analysis was made in 5 patients with PTLD, including 4 cases of M-PTLD with gene rearrangement and 1 case of P-PTLD without gene rearrangement. Univariate analysis showed that age (≤18 years old) was associated with poor prognosis (P = 0.040). Conclusions The clinicopathologic features of PTLD are various and infected by EB virus. Gene rearrangement can help the diagnosis. Key words: Lymphoproliferative disorders; Transplantation; Herpesvirus 4, human; Pathology, clinical
{"title":"Posttransplant lymphoproliferative disorders: a clinicopathological analysis of 11 cases","authors":"B. Nie, Xin Huang, Lin Sun, Xiaolong Liu, L. Kong, Zi-fen Gao","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.009","url":null,"abstract":"Objective \u0000To analyze the clinicopathological features of the posttransplant lymphoproliferative disorders (PTLD) and to improve the diagnostic levels. \u0000 \u0000 \u0000Methods \u0000The clinical data of 11 patients diagnosed with PTLD between January 2008 and January 2018 from Henan Provincial People's Hospital, Peking University Science Center and the Affiliated Third Hospital of Peking University were collected. The clinicopathological features and the potential prognostic predictors were retrospectively analyzed by using immunohistochemical staining, EB virus in situ hybridization, fluorescence in situ hybridization and gene sequencing. \u0000 \u0000 \u0000Results \u0000There were 9 males and 2 females in 11 PTLD patients, and the median age of the total patients was 18 years old (3-34 years old). The median time of 9 cases who underwent hematopoietic stem cell transplantation developing PTLD was 4 months (2-24 months) after the transplantation. The other 2 cases undergoing solid organ transplantation (SOT) occurred PTLD after 6 months and 13 months, respectively. The lymph node was the most common site to be involved (9 cases), 1 case occurred in liver and 1 case occurred in nasopharynx site. Among 11 patients, 3 cases were classified as polymorphic PTLD (P-PTLD) and the other 8 cases were monomorphic PTLD (M-PTLD). EB virus of all cases was positive, and 8 cases of M-PTLD were classified as diffuse large B-cell lymphoma (DLBCL). Fluorescence in situ hybridization was used to detect bcl-2, myc, IGH and A20 gene, and only one case had the gene break of IGH, while other cases didn't find any other abnormalities. Ig gene clone analysis was made in 5 patients with PTLD, including 4 cases of M-PTLD with gene rearrangement and 1 case of P-PTLD without gene rearrangement. Univariate analysis showed that age (≤18 years old) was associated with poor prognosis (P = 0.040). \u0000 \u0000 \u0000Conclusions \u0000The clinicopathologic features of PTLD are various and infected by EB virus. Gene rearrangement can help the diagnosis. \u0000 \u0000 \u0000Key words: \u0000Lymphoproliferative disorders; Transplantation; Herpesvirus 4, human; Pathology, clinical","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45668337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To explore the physical condition, quality of life, and efficacy of esophageal cancer radiotherapy patients with different nutritional status. Method: A retrospective analysis was conducted on 62 patients with esophageal squamous cell carcinoma admitted to Shanxi Cancer Hospital from December 2017 to December 2018. According to the subjective overall evaluation scale developed by the patients, they were divided into a group with good nutritional status (Group A) of 18 cases, a group with mild to moderate malnutrition (Group B) of 25 cases, and a group with severe malnutrition (Group C) of 19 cases. All patients received local radical radiotherapy. Compare the physical condition, quality of life, recent efficacy, and incidence of radiation esophagitis among patients in each group before and after radiotherapy. The Karnofsky score and quality of life score at the end of radiotherapy and 3 months after radiotherapy in Group A were better than those in Group B and Group C (both P<0.05). The quality of life scores of patients in each group decreased at the end of radiotherapy compared to before, and increased three months after radiotherapy compared to before and after radiotherapy. The recent effective rate in Group A was 94.4% (17/18), Group B was 92.0% (23/25), and Group C was 89.5% (17/19). There was no statistically significant difference among the three groups（ χ 2=0.778, P=1.00). The incidence of grade 2-3 radiation esophagitis in Group A was 22.2% (4/18), Group B was 24.0% (6/25), and Group C was 68.4% (13/19), with statistically significant differences among the three groups（ χ 2=11.534, P=0.003). Conclusion: Nutritional status is related to the patient's physical condition, quality of life, and degree of radiation esophagitis. Good nutritional status can improve the patient's tolerance to treatment.
{"title":"A clinical analysis of esophageal cancer patients in different nutritional status treated with radiotherapy","authors":"Zhetao Mi, Xiufu Zhang, Jin Gu, Zhifang Zang, Wenli Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.015","url":null,"abstract":"目的 \u0000探讨不同营养状况食管癌放疗患者体力状况、生命质量及疗效。 \u0000 \u0000 \u0000方法 \u0000回顾性分析2017年12月至2018年12月山西省肿瘤医院收治的食管鳞状细胞癌患者62例，根据患者产生的主观整体评估量表分为营养状况良好组（A组）18例、轻中度营养不良组（B组）25例、重度营养不良组（C组）19例。所有患者均接受局部根治性放疗。比较各组患者放疗前后体力状况、生命质量、近期疗效及放射性食管炎发生情况。 \u0000 \u0000 \u0000结果 \u0000A组放疗结束时及放疗结束3个月Karnofsky评分及生命质量评分均优于B组及C组（均P<0.05）。各组患者放疗结束时生命质量评分均较放疗前降低，放疗结束3个月较放疗结束时及放疗前升高。A组近期有效率为94.4%（17/18），B组为92.0%（23/25），C组为89.5%（17/19），三组差异无统计学意义（χ2=0.778，P=1.000）。A组2~3级放射性食管炎发生率为22.2%（4/18），B组为24.0%（6/25），C组为68.4%（13/19），三组差异有统计学意义（χ2=11.534，P=0.003）。 \u0000 \u0000 \u0000结论 \u0000营养状况与患者体力状况、生命质量及放射性食管炎发生程度相关，营养状况良好可提高患者对治疗的耐受性。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45850281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Application of recombinant human thrombopoietin combined with granulocyte colony-stimulating factor in autologous peripheral blood stem cell mobilization of non-Hodgkin lymphoma","authors":"Jin Zhao, L. Su, Jiangtao Wang, T. Guan, Xiaolan Liu, Li Ma","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.014","url":null,"abstract":"目的 \u0000探讨重组人血小板生成素（rhTPO）在非霍奇金淋巴瘤（NHL）患者自体外周血干细胞动员及采集中的作用。 \u0000 \u0000 \u0000方法 \u0000选取2013年5月至2018年5月在山西医科大学附属肿瘤医院行自体外周血干细胞移植的50例NHL患者，比较化疗联合重组人粒细胞集落刺激因子（G-CSF）组和大剂量依托泊苷、G-CSF联合rhTPO组的疗效。 \u0000 \u0000 \u0000结果 \u000050例患者动员、采集、造血重建均顺利完成，无一例移植相关死亡。全部患者共行119例次外周血干细胞采集，获得单个核细胞（5.66±1.11）×108/kg，获得CD34+细胞（2.15±1.20）×106/kg。依托泊苷（VP16）、G-CSF联合rhTPO组在单次采集达标率、CD34+细胞数量方面均好于化疗联合G-CSF组（P=0.000 1，P=0.031）。两组在单个核细胞、中性粒细胞、血小板恢复时间及成分血输注上差异均无统计学意义（均P>0.05）。 \u0000 \u0000 \u0000结论 \u0000rhTPO联合大剂量VP16、G-CSF方案用于NHL患者自体外周血造血干细胞动员及采集安全有效，总体成功率高，不良反应可控。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44757649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.003
Zhongying Li, Weihong Wang, Hao Qi, Bingshan Wu, P. Gao, Jingtao Wang
Objective To investigate the effect of histone deacetylase inhibitor apicidin on the glioblastoma U87 cells and its regulation of OCT-4 gene expression. Methods Glioblastoma U87 cells were treated with different concentrations of apicidin, and dimethyl sulfoxide instead of apicidin was negative control. Methyl thiazolyl tetrazolium (MTT) assay was used to detect the proliferative ability of U87 cells treated by apicidin. The cell apoptosis was observed under the fluorescence microscope, and the cell cycle was detected by using flow cytometry. Reverse transcription-polymerase chain reaction and Western blot was used to detect the expression of mRNA and protein of U87 cells, respectively relative to the expression of GAPDH. Results MTT assay results showed that apicidin inhibited U87 cells proliferation in a dose-dependent and time-dependent manner, and half of the inhibitory concentration of cell proliferation at 48 h was (1.74±0.13) μmol/L. The cell proportion of U87 cells in S-phase of the negative control, 0.2, 0.5, and 1.0 μmol/L apicidin was (32.68±0.49)%, (33.73±0.76)%, (42.92±0.56)%, and (56.95±0.53)%, respectively after 48 h apicidin administration (P < 0.05), while the proportion of G1 and G2 phase cells was decreased. The karyopyknosis and other apoptotic changes were detected in U87 cells after 48 h treatment of 1.0 μmol/L apicidin under the confocal fluorescence microscope. Western blot and RT-PCR showed that the mRNA and protein relative levels of U87 cells OCT-4 were reduced after 1.0 μmol/L apicidin treatment for 48 h compared with the negative control group (mRNA: 72.44±0.00 vs. 56.66±0.23; protein: 86.59±0.19 vs. 56.04±0.15, both P < 0.01). Conclusions Apicidin can inhibit the growth of glioblastoma U87 cells, induce cell cycle arrest and apoptosis. Its mechanism may be related to the expression of OCT-4 inhibited by apicidin. Key words: Glioma; Histone deacetylases; OCT-4; Epigenomics
{"title":"Effect of apicidin on glioblastoma U87 cells and its regulation of OCT-4 gene expression","authors":"Zhongying Li, Weihong Wang, Hao Qi, Bingshan Wu, P. Gao, Jingtao Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.003","url":null,"abstract":"Objective \u0000To investigate the effect of histone deacetylase inhibitor apicidin on the glioblastoma U87 cells and its regulation of OCT-4 gene expression. \u0000 \u0000 \u0000Methods \u0000Glioblastoma U87 cells were treated with different concentrations of apicidin, and dimethyl sulfoxide instead of apicidin was negative control. Methyl thiazolyl tetrazolium (MTT) assay was used to detect the proliferative ability of U87 cells treated by apicidin. The cell apoptosis was observed under the fluorescence microscope, and the cell cycle was detected by using flow cytometry. Reverse transcription-polymerase chain reaction and Western blot was used to detect the expression of mRNA and protein of U87 cells, respectively relative to the expression of GAPDH. \u0000 \u0000 \u0000Results \u0000MTT assay results showed that apicidin inhibited U87 cells proliferation in a dose-dependent and time-dependent manner, and half of the inhibitory concentration of cell proliferation at 48 h was (1.74±0.13) μmol/L. The cell proportion of U87 cells in S-phase of the negative control, 0.2, 0.5, and 1.0 μmol/L apicidin was (32.68±0.49)%, (33.73±0.76)%, (42.92±0.56)%, and (56.95±0.53)%, respectively after 48 h apicidin administration (P < 0.05), while the proportion of G1 and G2 phase cells was decreased. The karyopyknosis and other apoptotic changes were detected in U87 cells after 48 h treatment of 1.0 μmol/L apicidin under the confocal fluorescence microscope. Western blot and RT-PCR showed that the mRNA and protein relative levels of U87 cells OCT-4 were reduced after 1.0 μmol/L apicidin treatment for 48 h compared with the negative control group (mRNA: 72.44±0.00 vs. 56.66±0.23; protein: 86.59±0.19 vs. 56.04±0.15, both P < 0.01). \u0000 \u0000 \u0000Conclusions \u0000Apicidin can inhibit the growth of glioblastoma U87 cells, induce cell cycle arrest and apoptosis. Its mechanism may be related to the expression of OCT-4 inhibited by apicidin. \u0000 \u0000 \u0000Key words: \u0000Glioma; Histone deacetylases; OCT-4; Epigenomics","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46062483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.016
Mingxiao Li, Haihui Jiang
Glioblastoma (GBM) is the most malignant primary brain tumor, and it has very poor prognosis. In recent years, the immunotherapy has become a hot issue in the treatment of malignancies. The traditional treatment regimen combined with immunotherapy might make a progress in the diagnosis and treatment of GBM. This paper reviews the explanation of the traditional chemoradiotherapy affecting the body's anti-tumor and immunity mechanism, and the current achievement of standard chemoradiotherapy combined with immunotherapy, to explore the potential benefits to GBM patients. Key words: Glioblastoma; Immunotherapy; Drug therapy, combination; Radiotherapy
{"title":"Effect of chemoradiotherapy on anti-tumor immunity of glioblastoma patients and treatment enlightement","authors":"Mingxiao Li, Haihui Jiang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.016","url":null,"abstract":"Glioblastoma (GBM) is the most malignant primary brain tumor, and it has very poor prognosis. In recent years, the immunotherapy has become a hot issue in the treatment of malignancies. The traditional treatment regimen combined with immunotherapy might make a progress in the diagnosis and treatment of GBM. This paper reviews the explanation of the traditional chemoradiotherapy affecting the body's anti-tumor and immunity mechanism, and the current achievement of standard chemoradiotherapy combined with immunotherapy, to explore the potential benefits to GBM patients. \u0000 \u0000 \u0000Key words: \u0000Glioblastoma; Immunotherapy; Drug therapy, combination; Radiotherapy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42122053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To investigate the safety and effectiveness of laser treatment for primary airway malignant tumors through rigid bronchoscopy. Method: A retrospective analysis was conducted on the clinical data of a patient with primary airway malignant tumor treated with laser intervention under rigid bronchoscopy at Lianyungang First People's Hospital, and relevant literature was reviewed. The results showed that the patient had significantly improved respiratory distress symptoms, fewer complications, and a good recovery after the rigid bronchoscopy intervention laser treatment. Conclusion: Laser treatment of malignant tumors in the main airway cavity through rigid bronchoscopy can help to clear the airway, immediately alleviate respiratory difficulties in patients, with fewer complications, and temporarily alleviate the condition for patients with bronchial malignant tumors without surgical opportunities.
{"title":"Laser treatment under rigid bronchoscopy for malignant airway tumors: report of one case and review of literature","authors":"Xiangzhen Meng, Jiwang Wang, Jiashu Li, Hong Zheng","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.11.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.11.015","url":null,"abstract":"目的 \u0000探讨经硬质支气管镜激光治疗主气道恶性肿瘤的安全性及有效性。 \u0000 \u0000 \u0000方法 \u0000回顾性分析连云港市第一人民医院收治的1例采用硬质支气管镜下激光介入治疗的主气道恶性肿瘤患者的临床资料，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000本例患者硬质支气管镜介入激光治疗术后呼吸困难症状明显改善，并发症少，恢复良好。 \u0000 \u0000 \u0000结论 \u0000经硬质支气管镜激光治疗主气道腔内恶性肿瘤，有助于疏通气道，即时缓解患者呼吸困难症状，并发症少，对于无手术机会的支气管恶性肿瘤患者可临时缓解病情。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48411631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the clinical characteristics and diagnosis of splenic in situ B-cell marginal zone lymphoma combined with pancreatic ductal papillary mucinous tumor (IPMN). Method: A retrospective analysis was conducted on the preoperative laboratory examination data, imaging data, and postoperative pathological data of a patient with splenic in situ B-cell marginal zone lymphoma complicated with IPMN admitted to the First Hospital of Jilin University, and the relevant literature was reviewed. The postoperative pathological result of the patient was splenic in situ B-cell marginal zone lymphoma with IPMN. Multi slice CT scan of liver, gallbladder, spleen, and pancreas combined with three phase enhanced scan shows low contrast enhancement in the body of the pancreas, considering space occupying lesions; The results of postoperative bone marrow biopsy showed no significant abnormalities in the morphology of nuclear cells. After 3 months of follow-up, no obvious abnormalities were found. Conclusion: In situ B-cell border zone lymphoma of the spleen with IPMN is very rare in clinical practice. The diagnosis of splenic marginal zone lymphoma and IPMN relies on histopathology and immunohistochemistry.
{"title":"Spleen in situ B-cell marginal zone lymphoma and pancreatic ductal papillary mucinous neoplasm: report of one case and review of literature","authors":"Shouqian Wang, Lei Liu, Changxu Li, Qingchun Guan, Yingchao Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.11.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.11.014","url":null,"abstract":"目的 \u0000探讨脾脏原位B细胞边缘区淋巴瘤合并胰腺导管内乳头状黏液性肿瘤（IPMN）的临床特征及诊断。 \u0000 \u0000 \u0000方法 \u0000回顾性分析吉林大学第一医院收治的1例脾脏原位B细胞边缘区淋巴瘤合并IPMN患者的术前实验室相关检查资料、影像学资料、术后病理资料，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者术后病理结果为脾脏原位B细胞边缘区淋巴瘤合并IPMN。肝胆脾胰多排CT平扫+三期增强扫描示胰体部低强化影，考虑占位性病变；术后骨髓穿刺活组织检查结果示有核细胞形态未见明显异常。术后3个月随访，未见明显异常。 \u0000 \u0000 \u0000结论 \u0000脾脏原位B细胞边缘区淋巴瘤合并IPMN临床上十分罕见。脾边缘区淋巴瘤和IPMN的诊断均依赖病理组织学和免疫组织化学。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42425729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：